Lp(a) level is associated with long-term adverse outcomes in patients with coronary heart disease  

作　　者：冯喆 刘勇 陈纪言 周颖玲 

机构地区：[1]Department of Cardiology,Guangdong Cardiovascular Institute,Guangdong Key Laboratory of Coronary Disease,Guangdong General Hospital,Guangdong Academy of Medical Sciences

出　　处：《South China Journal of Cardiology》2017年第1期12-20,共9页岭南心血管病杂志（英文版）

基　　金：supported by Guangdong Provincial Cardiovascular Clinical Medicine Research Fund(No.2009X41 by Yong Liu and Ning Tan);Science and Technology Planning Project of Guangdong Province(PRECOMIN study by Yong Liu in 2011 and study grant No.2008A030201002 by Ji-yan Chen);Guangdong Cardiovascular Institute;supported by Progress of science and technology project in Guangdong province(No2013b031800025/2016b020215130);Cadiovascular Research Foundation Project of Chinese Medical Doctor Association(No.SCRFCMDA201216);the National Natural Science Foundation of China(No.81470571)

摘　　要：Background Mounting evidence has suggested that high level of Lipoprotein （a） （Lp [a] ） is associated with increased risk of coronary heart disease （CHD）. However, the impact of Lp （a） on long-term adverse outcomes of CHD undergone coronary angiography （CAG） or percutaneous coronary intervention （PCI） has not been fully examined. Methods We enrolled 1684 patients with CHD between October 2009 and December 2013. The patients were divided into two group according to their median plasma Lp （a） levels： Lp （a）〈16.03 mg/dL （n= 842 patients）, and Lp （a） ≥ 16.03 mg/dL （n=842 patients）. Kaplan-Meier curve was carried out examining the survival time between the two groups. The associations of Lp （a） levels and long-term major adverse cardiovascu- lar events （MACEs） were investigated by cox regression analysis. Results Patients with the high Lp（a） did not have an increased risk of in-hospital MACEs （3.0% vs. 1.7%, P=0.075）, but had a higher long-term MACEs than those in the low Lp（a） group （6.3% vs. 3.1%, P=0.005）. With the median follow-up period of 1.94 years, multivariate Cox regression analysis revealed that a higher Lp （a） level was an independent predictor of longterm MACEs （hazard ratio 1.82, 95% confidence interval 1.04 to 3.18, P=0.036）. Conclusion An elevated level of Lp（a） is significantly associated with long-term adverse outcomes in patients with CHD following CAG or PCI.Background Mounting evidence has suggested that high level of Lipoprotein （a） （Lp [a] ） is associated with increased risk of coronary heart disease （CHD）. However, the impact of Lp （a） on long-term adverse outcomes of CHD undergone coronary angiography （CAG） or percutaneous coronary intervention （PCI） has not been fully examined. Methods We enrolled 1684 patients with CHD between October 2009 and December 2013. The patients were divided into two group according to their median plasma Lp （a） levels： Lp （a）〈16.03 mg/dL （n= 842 patients）, and Lp （a） ≥ 16.03 mg/dL （n=842 patients）. Kaplan-Meier curve was carried out examining the survival time between the two groups. The associations of Lp （a） levels and long-term major adverse cardiovascu- lar events （MACEs） were investigated by cox regression analysis. Results Patients with the high Lp（a） did not have an increased risk of in-hospital MACEs （3.0% vs. 1.7%, P=0.075）, but had a higher long-term MACEs than those in the low Lp（a） group （6.3% vs. 3.1%, P=0.005）. With the median follow-up period of 1.94 years, multivariate Cox regression analysis revealed that a higher Lp （a） level was an independent predictor of longterm MACEs （hazard ratio 1.82, 95% confidence interval 1.04 to 3.18, P=0.036）. Conclusion An elevated level of Lp（a） is significantly associated with long-term adverse outcomes in patients with CHD following CAG or PCI.

关 键 词：lipoprotein（a） coronary heart disease major adverse cardiovascular events 

分 类 号：R541.4[医药卫生—心血管疾病]